MIT researchers have developed VaxSeer, an AI system that predicts which influenza strains will dominate and which vaccines will offer the best protection, aiming to reduce guesswork in seasonal flu vaccine selection.
Using deep learning on decades of viral sequences and lab data, VaxSeer outperformed the World Health Organization’s strain choices in 9 of 10 seasons for H3N2 and 6 of 10 for H1N1 in retrospective tests.
Published in Nature Medicine, the study suggests VaxSeer could improve vaccine effectiveness and may eventually be applied to other rapidly evolving health threats such as antibiotic resistance or drug-resistant cancers.
The study, published in Nature Medicine, was authored by lead researcher Wenxian Shi along with Regina Barzilay, Jeremy Wohlwend, and Menghua Wu. It was supported in part by the U.S. Defense Threat Reduction Agency and MIT’s Jameel Clinic.
According to MIT, the system, called VaxSeer, was developed by scientists at MIT’s Computer Science and Artificial Intelligence Laboratory and the MIT Jameel Clinic for Machine Learning in Health. It uses deep learning models trained on decades of viral sequences and lab results to forecast which flu strains are most likely to dominate and how well candidate vaccines will work against them. Unlike traditional approaches that evaluate single mutations in isolation, VaxSeer’s large protein language model can capture the combined effects of multiple mutations and model shifting viral dominance more accurately.
“VaxSeer adopts a large protein language model to learn the relationship between dominance and the combinatorial effects of mutations,” Shi noted. “Unlike existing protein language models that assume a static distribution of viral variants, we model dynamic dominance shifts, making it better suited for rapidly evolving viruses like influenza.”
In retrospective tests covering ten years of flu seasons, VaxSeer’s strain recommendations outperformed those of the World Health Organization in nine of ten cases for H3N2 influenza, and in six of ten cases for H1N1, researchers said. In one notable example, the system correctly identified a strain for 2016 that the WHO did not adopt until the following year. Its predictions also showed strong correlation with vaccine effectiveness estimates reported by U.S., Canadian, and European surveillance networks.
The tool works in two parts: one model predicts which viral strains are most likely to spread, while another evaluates how effectively antibodies from vaccines can neutralize them in common hemagglutination inhibition assays. These predictions are then combined into a coverage score, which estimates the likely effectiveness of a candidate vaccine months before flu season begins.
“Given the speed of viral evolution, current therapeutic development often lags behind. VaxSeer is our attempt to catch up,” Barzilay noted.
RENO, Nev., Sept. 02, 2025 (GLOBE NEWSWIRE) — GreetEat Corporation (OTC: GEAT), a forward-thinking technology company dedicated to building next-generation platforms, today announced the official re-launch of its subsidiary Wall Street Stats (WallStreetStats.io) applications on both iOS and Android. The updated apps deliver a powerful suite of new tools designed to empower investors with deeper insights, smarter analytics, and a cutting-edge user experience.
The new release introduces an upgraded platform driven by artificial intelligence and machine learning, providing users with:
Detailed Quotes & Company Profiles – Comprehensive financial data with intuitive visualization.
Summarized Market Intelligence – AI-powered data aggregation and automated summarization for faster decision-making.
Sentiment Analysis via Reddit & Social Platforms – Machine learning models that detect, classify, and quantify investor sentiment in real time.
Trending Stocks, Top Gainers, Top Losers, and Most Active Lists – AI-curated market movers updated dynamically throughout the day.
Smart Watchlists – Personalized watchlists enhanced by predictive analytics and recommendation algorithms.
AI-Driven Market Predictions – Leveraging natural language processing (NLP), deep learning, and behavioral pattern recognition to uncover emerging investment opportunities.
“Wall Street Stats was designed to go beyond traditional financial data and offer an AI-first experience that empowers both retail and professional investors,” said Victor Sima, CTO of GreetEat Corporation. “With this re-launch, we’ve combined the best of real-time market intelligence with machine learning powered insights that make data more actionable, intuitive, and predictive. This is just the beginning of our vision to democratize Wall Street – level analytics for everyone.”
The platform’s enhanced features are aimed at giving investors a competitive edge by uncovering hidden patterns, predicting momentum, and providing smarter investment signals. With natural language processing, predictive modeling, and real-time data analytics, Wall Street Stats represents a new era in financial technology innovation.
About GreetEat Corporation GreetEat Corporation (OTC: GEAT) is a technology-driven platform designed to bring people together through virtual dining. Whether for business meetings, celebrations, or personal connections, GreetEat blends video conferencing with meal delivery to create meaningful, shared experiences anywhere in the world. In addition to GreetEat.com, the company also owns WallStreetStats.io, a cutting-edge fintech app that leverages AI and machine learning to analyze social sentiment, market trends, and trading signals in real time, available on both Android and iOS stores.
Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates, and projections about the company’s business and industry, management’s beliefs, and certain assumptions made by the management. Such statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
New grant money from Natural Sciences and Engineering Research Council of Canada (NSERC) will help Algoma University researchers continue their work in artificial intelligence, renewable energy, and sustainable farming and biotechnology.
The Sault Ste. Marie university announced Aug. 28 it will receive $541,000 over five years toward three projects at the school.
Dr. Ping Luo is developing artificial intelligence (AI) tools to detect cancer earlier and more accurately, paving the way for faster diagnoses and more personalized care.
Dr. Syed Muhammad Danish is designing smarter, greener infrastructure for electric vehicles and renewable energy systems, while embedding sustainable practices into generative AI to support Canada’s net-zero goals.
Dr. Isabel Molina, a Tier II Canada Research Chair, is investigating how plants naturally produce protective compounds, with the potential to transform sustainable farming and biotechnology.
“From cancer research to clean energy and sustainable agriculture, world-class innovation is thriving right here in Northern Ontario,” Brett Goodwin, Algoma’s interim vice-president of academic and research, said in a news release.
“Our faculty are leading research in computer science, life sciences, and environmental innovation to tackle urgent global challenges, while creating exceptional learning opportunities for our students, including students in our recently launched graduate programs in biology and computer science.”
FLORENCE, Italy, Sept. 2, 2025/PRNewswire/ — Medical Horizons S.r.l., (medicalhorizons.it) a leading distributor of Artificial Intelligence (AI) solutions for healthcare, today announced an exclusive distribution agreement with Bowhead Health Inc.(bowheadhealth.com), a Canadian innovator in secure health data management and AI-powered clinical trial matching.
Under this agreement, Medical Horizons becomes the exclusive partner for Bowhead Health in Italy, Turkey, and Cyprus, expanding access to advanced technologies that improve clinical trial recruitment, optimize research workflows, and strengthen hospital and research institute capabilities across the region.
Addressing Healthcare’s Urgent Needs Healthcare systems worldwide face growing challenges from workforce shortages and rising clinical demands. Artificial intelligence is increasingly recognized as a critical tool to help address these pressures, enabling hospitals and researchers to deliver faster, more personalized care.
“Manual clinical trial matching is slow, burdensome, and often misses the genomic details that matter most,” said Francisco Diaz-Mitoma, CEO of Bowhead Health Inc. “Our platform allows hospitals to scan global and local trial databases instantly, helping them connect patients with the right therapies far more efficiently.”
Bowhead’s AI-driven technology reduces time spent on manual searches, simplifies workflows, and provides confidence for both researchers and patients, accelerating progress toward personalized medicine.
A Strategic Expansion for Medical Horizons For Medical Horizons, the partnership marks a continuation of its mission to bring best-in-class AI technologies to European healthcare providers.
“This collaboration represents a decisive step in our strategy to deliver practical, high-impact AI solutions,” said Guido Osti, CEO of Medical Horizons. “Bowhead Health has developed a unique platform that combines secure health data management, artificial intelligence, and clinical research. We are proud to guide their expansion in Italy, Turkey, and Cyprus.”
Bowhead Health Inc. Based in Ottawa, Canada, Bowhead Health has developed a secure digital ecosystem that integrates:
An AI-powered trial matching engine for personalized patient recruitment.
A de-identified health data platform compliant with GDPR, HIPAA, and global security standards.
Collaborative digital flows connecting patients, hospitals, researchers, and pharmaceutical companies.
Bowhead Health is currently validating its technology with leading hospitals in Canada, Europe, India, and the United States, with strong early results.
